Search Results for "Suvorexant"
Original Source: Promotion of Sleep by Suvorexant-A Novel Dual Orexin Receptor Antagonist.
Abstract: Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits. Two receptors respond to orexin signaling, orexin 1 receptor (OX(1)R) and orexin 2 receptor (OX(2)R) with partially overlapping nervous system distributions. Genetic studies suggest orexin receptor antagonists could be therapeutic for insomnia and other disorders with disruptions of sleep and wake. Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX...
Matching Channels
None
Matching News
Merck & Co has reported positive new data for its investigational insomnia drug suvorexant. The data show that patients who had been taking suvorexant for 12 months and were immediately switched to p...
Merck & Co rests easy following more positive suvorexant data
Merck & Co has reported positive new data for its investigational insomnia drug suvorexant. The data show that patients who had been taking suvorexant for 12 months and were immediately switched to p...
New Phase III Data Showed Mercks Investigational Insomnia Medicine Suvorexant Improved ...
Suvorexant Achieved Statistical Significance on 15 of 16 Primary Endpoints Merck Remains on Track to File a New Drug Application for Suvorexant in 2012, One of the Six Major Pipeline Fili...
FDA staff say Merck's sleep drug effective, question dose levels
May 20 (Reuters) - *FDA STAFF REVIEWERS SAY CLINICAL TRIALS OF MERCK'S SLEEP DRUG SUVOREXANT "OVERALL, ESTABLISH EFFECTIVENESS." *FDA STAFF REVIEWERS SAY SUVOREXANT SEEMS TO BE ASSOCIATED WITH EVENTS...
FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg
US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's investigational insomnia drug candidate, has been accepted for standard review by the US Food and...
Merck's insomnia drug suvorexant to get 'standard' US review
The US FDA has accepted Merck's new drug application (NDA) for suvorexant as a treatment for insomnia, granting a standard review. Merck noted that if the FDA grants its blessing to suvorexant, th...
FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet on May 22 to discuss an NDA from Merck & Co. Inc. (NYSE:MRK) for suvorexant to treat insomnia. Merck declined to disclose...
Merck's suvorexant meets Phase III insomnia endpoints
Merck & Co. Inc. (NYSE:MRK) reported positive data from two identical Phase III trials evaluating high-dose suvorexant (MK-4305) to treat insomnia at the SLEEP 2012 meeting in Boston. In the first tri...
Matching PubMed Articles
STUDY OBJECTIVES: Suvorexant (MK-4305) is an orexin receptor antagonist being developed for the treatment of insomnia. This report describes the effects of nighttime administration of suvorexant on po...
Promotion of Sleep by Suvorexant-A Novel Dual Orexin Receptor Antagonist.
Abstract: Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits. Two receptors respond to orexin signaling, orexin 1 receptor (OX(1)R) and orexin 2 r...
The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin ant...
Orexin A and orexin B are hypothalamic neuropeptides initially identified as endogenous ligands for two orphan G-protein coupled receptors (GPCRs). They play critical roles in the maintenance of wakef...
Enantioselective synthesis of a dual orexin receptor antagonist.
A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. Key features of the synthesis include a mild copper-catalyzed amination, a highly chemoselective c...
